New
Overview of Vitiligo Research April - June 2014
Published today. Thirty six PubMed records were found by our Chief Scientific Director Dr. Korobko to be relevant and of interest, and were included into this quarterly overview. The review includes sections on epidemiology, comorbidities, quality of life, vitiligo triggers, new case reports, new clinical studies and trials, analysis of mechanisms of vitiligo pathogenesis, genetic studies, candidate biomarkers, mechanisms of treatments, methodological advancements and novel treatment modalities.
FAQOther Questions
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Safety of clinical trials. Can my child leave it for any reason?
Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.